tbuckley/cabot-search huggingface dataset:
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study
Authors: Alyn Morice, Jaclyn A. Smith, Lorcan McGarvey, Surinder S. Birring, Sean M. Parker, Alice Turner, Thomas Hummel, Isabella Gashaw, Lueder Fels, Stefan Klein, Klaus Francke, Christian Friedrich
Journal: European Respiratory Journal (2021)

ATP acting via P2X3 receptors is an important mediator of refractory chronic cough (RCC). This phase 2a double-blinded crossover study assessed the safety, tolerability and efficacy of eliapixant (BAY 1817080), a selective P2X3 receptor antagonist, in adults with RCC attending specialist centres.In period A, patients received placebo for 2 weeks then eliapixant 10 mg for 1 week. In period B, patients received eliapixant 50, 200 and 750 mg twice daily for 1 week per dose level. Patients were randomised 1:1 to period A-B (n=20) or B-A (n=20). The primary efficacy end-point was change in cough frequency assessed over 24 h. The primary safety end-point was frequency and severity of adverse events (AEs).37 patients completed randomised therapy. Mean cough frequency fell by 17.4% versus baseline with placebo. Eliapixant reduced cough frequency at doses ≥50 mg (reduction versus placebo at 750 mg: 25% (90% CI 11.5-36.5%); p=0.002). Doses ≥50 mg also significantly reduced cough severity. AEs, mostly mild or moderate, were reported in 65% of patients with placebo and 41-49% receiving eliapixant. Cumulative rates of taste-related AEs were 3% with placebo and 5-21% with eliapixant; all were mild.Selective P2X3 antagonism with eliapixant significantly reduced cough frequency and severity, confirming this as a viable therapeutic pathway for RCC. Taste-related side-effects were lower at therapeutic doses than with the less selective P2X3 antagonist gefapixant. Selective P2X3 antagonism appears to be a novel therapeutic approach for RCC.
Correction to: Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells
Authors: Yahui Ding, Huier Gao, Yu Zhang, Ye Li, Neil Vasdev, Yingdai Gao, Yue Chen, Quan Zhang
Journal: Journal of Hematology & Oncology (2021)

An amendment to this paper has been published and can be accessed via the original article.
Are balloon enteroscopy-assisted ERCP and laparoscopy-assisted ERCP in Roux-en-Y gastric bypass equivalent?
Authors: Harry Martin, George Webster
Journal: Endoscopy (2021)

See also: Laparoscopy-assisted versus balloon enteroscopy-assisted ERCP after Roux-en-Y gastric bypass Endoscopy 2020; 52(08): 654-661DOI: 10.1055/a-1139-9313
Reciprocal Tears
Authors: Faith T. Fitzgerald
Journal: Annals of Internal Medicine (2019)

On Being a Doctor17 September 2019Reciprocal TearsFaith T. Fitzgerald, MDFaith T. Fitzgerald, MDUC Davis Medical Center, Sacramento, California (F.T.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-0193 Audio Reading - “Reciprocal Tears” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Reciprocal Tears” by Faith T. Fitzgerald, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail An intern assigned to see a woman in the general medicine outpatient clinic entered the room where the patient waited; he then promptly exited. As he left, his loud voice could be heard throughout the area saying only, “Lose weight!”Far down the hall I could hear both his scorn and her uncontrollable crying. I was her attending. I rushed to her room and through the open door and saw the tears streaming down her face.I commanded the intern to leave the area. I was in no mood to suffer fools. As he started to argue with me, I ... Author, Article, and Disclosure InformationAffiliations: UC Davis Medical Center, Sacramento, California (F.T.F.)Corresponding Author: Faith T. Fitzgerald, MD, UC Davis Medical Center, C/O Division of General Medicine, 4150 V Street, Suite 2400, Sacramento, CA 95817; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Reciprocal Tears” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Reciprocal Tears” by Faith T. Fitzgerald, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 17 September 2019Volume 171, Issue 6Page: 436KeywordsCaregiversDietFatsHeart failureOutpatient clinicsOverweightRunningSurgeryWeight gainWeight loss ePublished: 17 September 2019 Issue Published: 17 September 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Re: Peng Xu, Binshen Chen, Abai Xu, Dan Yuan, Yiming Zhang, Chunxiao Liu. Initial Experience with Intracorporeal Laparoscopic Radical Cystectomy and Detaenial Sigmoid Neobladder Reconstruction. Eur Urol 2021;79:545–51
Authors: Lindsay Nelson, Abubaker Ali, Shaheen Alanee
Journal: European Urology (2021)
Blunt Splenic Injury and Prophylactic Splenic Artery Embolization
Authors: Rebecca Windle, Giordano Perin, Saba P. Balasubramanian
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results?
Authors: Hironobu Minami, Naomi Kiyota, Takashi Omori
Journal: Journal of Clinical Oncology (2021)

In their publication of the KEYNOTE-181 study results in Journal of Clinical Oncology, Kojima et al 1 reported that the overall survival (OS) of patients with esophageal cancer with a programmed death ligand-1 (PD-L1) combined positive score (CPS) $ 10 was prolonged when pembrolizumab rather than chemotherapy was used as the second-line treatment.Median OS was 9.3 versus 6.7 months with a hazard ratio (HR) of 0.69, and the authors reported that this difference met the prespecified boundary for showing superiority (P , .00853).
Continued versus discontinued oxytocin stimulation in the active phase of labour (CONDISOX): double blind randomised controlled trial
Authors: Sidsel Boie, Julie Glavind, Niels Uldbjerg, Philip J Steer, Pinar Bor
Journal: BMJ (2021)

Abstract Objective To determine whether discontinuing oxytocin stimulation in the active phase of induced labour is associated with lower caesarean section rates. Design International multicentre, double blind, randomised controlled trial. Setting Nine hospitals in Denmark and one in the Netherlands between 8 April 2016 and 30 June 2020. Participants 1200 women stimulated with intravenous oxytocin infusion during the latent phase of induced labour. Intervention Women were randomly assigned to have their oxytocin stimulation discontinued or continued in the active phase of labour. Main outcome measure Delivery by caesarean section. Results A total of 607 women were assigned to discontinuation and 593 to continuation of the oxytocin infusion. The rates of caesarean section were 16.6% (n=101) in the discontinued group and 14.2% (n=84) in the continued group (relative risk 1.17, 95% confidence interval 0.90 to 1.53). In 94 parous women with no previous caesarean section, the caesarean section rate was 7.5% (11/147) in the discontinued group and 0.6% (1/155) in the continued group (relative risk 11.6, 1.15 to 88.7). Discontinuation was associated with longer duration of labour (median from randomisation to delivery 282 v 201 min; P&lt;0.001), a reduced risk of hyperstimulation (20/546 (3.7%) v 70/541 (12.9%); P&lt;0.001), and a reduced risk of fetal heart rate abnormalities (153/548 (27.9%) v 219/537 (40.8%); P&lt;0.001) but rates of other adverse maternal and neonatal outcomes were similar between groups. Conclusions In a setting where monitoring of the fetal condition and the uterine contractions can be guaranteed, routine discontinuation of oxytocin stimulation may lead to a small increase in caesarean section rate but a significantly reduced risk of uterine hyperstimulation and abnormal fetal heart rate patterns. Trial registration ClinicalTrials.gov NCT02553226 .
Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era
Authors: Bei Hu, Xiao Lin, Hans C. Lee, Xuelin Huang, Rebecca Slack, Elias J. Jabbour, Srdan Verstovsek, Farhad Ravandi, Guillermo Garcia-Manero, Richard E Champlin, Zhen-Huan Hu, Kwang Woo Ahn, Ying Lee, Uday Popat, Ronald Sobecks, Edwin Alyea, Hagop M. Kantarjian, Jorge E. Cortes, Wael Saber
Journal: Blood (2017)
Deconvoluting global cytokine signaling networks in natural killer cells
Authors: Gabriela M. Wiedemann, Endi K. Santosa, Simon Grassmann, Sam Sheppard, Jean-Benoît Le Luduec, Nicholas M. Adams, Celeste Dang, Katharine C. Hsu, Joseph C. Sun, Colleen M. Lau
Journal: Nature Immunology (2021)
Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia
Authors: Yasser Sakr, Hatim Bensasi, Ahmed Taha, Michael Bauer, Khaled Ismail, Ghazala Belhaj, Khaled M. Afet, Dnyanwshwar Munde, David Monk, Samuel Buschbeck
Journal: Intensive Care Medicine (2021)
Carlos Michael Azurdia
Authors: Richard Azurdia
Journal: BMJ (2021)

Carlos Michael Azurdia’s paternal grandfather emigrated to Liverpool in 1910 with his large family, was appointed consul general for Guatemala in Liverpool and continued to practise medicine there. His father qualified as a doctor at Liverpool University in 1923 and was a GP for 30 years; he too was honorary consul general for Guatemala in 1950 until …
Hand eczema and temporal variation of Staphylococcus aureus clonal complexes: A prospective observational study
Authors: Line B Nørreslet, Sofie M Edslev, Maja-Lisa Clausen, Esben M Flachs, Niels E Ebbehøj, Paal S Andersen, Tove Agner
Journal: Journal of the American Academy of Dermatology (2021)
Applications of iPSC-derived beta cells from patients with diabetes
Authors: Kristina G. Maxwell, Jeffrey R. Millman
Journal: Cell Reports Medicine (2021)

Improved stem cell-derived pancreatic islet (SC-islet) differentiation protocols robustly generate insulin-secreting β cells from patient induced pluripotent stem cells (iPSCs). These advances are enabling in vitro disease modeling studies and the development of an autologous diabetes cell replacement therapy. SC-islet technology elucidates key features of human pancreas development and diabetes disease progression through the generation of pancreatic progenitors, endocrine progenitors, and β cells derived from diabetic and nondiabetic iPSCs. Combining disease modeling with gene editing and next-generation sequencing reveals the impact of diabetes-causing mutations and diabetic phenotypes on multiple islet cell types. In addition, the supply of SC-islets, containing β and other islet cell types, is unlimited, presenting an opportunity for personalized medicine and overcoming several disadvantages posed by donor islets. This review highlights relevant studies involving iPSC-β cells and progenitors, encompassing new conclusions involving cells from patients with diabetes and the therapeutic potential of iPSC-β cells.
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial
Authors: Keunchil Park, Mustafa Özgüroğlu, Johan Vansteenkiste, David Spigel, James C.H. Yang, Hidenobu Ishii, Marina Garassino, Filippo de Marinis, Aleksandra Szczesna, Andreas Polychronis, Ruchan Uslu, Maciej Krzakowski, Jong-Seok Lee, Luana Calabrò, Osvaldo Arén Frontera, Huiling Xiong, Marcis Bajars, Mary Ruisi, Fabrice Barlesi
Journal: Journal of Thoracic Oncology (2021)

In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data.Patients with stage IIIB or IV or recurrent NSCLC with disease progression after platinum-doublet chemotherapy were randomized 1:1 to avelumab 10 mg/kg every 2 weeks or docetaxel 75 mg/m2 every 3 weeks. The primary end point was OS in patients with PD-L1+ tumors (greater than or equal to 1% tumor cell expression; IHC 73-10 pharmDx assay).Of 792 patients, 529 had PD-L1+ tumors (264 versus 265 in the avelumab versus docetaxel arms, respectively). As of March 4, 2019, median duration of follow-up for OS in the PD-L1+ population was 35.4 months in the avelumab arm and 34.7 months in the docetaxel arm; study treatment was ongoing in 25 (9.5%) versus 0 patients, respectively. In the PD-L1+ population, 2-year OS rates (95% confidence interval [CI]) with avelumab versus docetaxel were 29.9% (24.5%-35.5%) versus 20.5% (15.6%-25.8%); in greater than or equal to 50% PD-L1+ subgroups, 2-year OS rates were 36.4% (29.1%-43.7%) versus 17.7% (11.8%-24.7%) and in the greater than or equal to 80% subgroup were 40.2% (31.3%-49.0%) versus 20.3% (12.9%-28.8%), respectively. Median duration of response (investigator assessed) was 19.1 months (95% CI: 10.8-34.8) versus 5.7 months (95% CI: 4.1-8.3). Safety profiles for both arms were consistent with the primary analysis.Although the JAVELIN Lung 200 primary analysis (reported previously) revealed that avelumab did not significantly prolong OS versus docetaxel in patients with platinum-treated PD-L1+ NSCLC, posthoc analyses at 2 years of follow-up revealed that 2-year OS rates were doubled with avelumab in subgroups with higher PD-L1 expression (greater than or equal to 50% and greater than or equal to 80%).
NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification
Authors: William M. Oldham, Anna R. Hemnes, Micheala A. Aldred, John Barnard, Evan L. Brittain, Stephen Y. Chan, Feixiong Cheng, Michael H. Cho, Ankit A. Desai, Joe G.N. Garcia, Mark W. Geraci, Susan D. Ghiassian, Kathryn T. Hall, Evelyn M. Horn, Mohit Jain, Rachel S. Kelly, Jane A. Leopold, Sara Lindstrom, Brian D. Modena, William C. Nichols, Christopher J. Rhodes, Wei Sun, Andrew J. Sweatt, Rebecca R. Vanderpool, Martin R. Wilkins, Beth Wilmot, Roham T. Zamanian, Joshua P. Fessel, Neil R. Aggarwal, Joseph Loscalzo, Lei Xiao
Journal: Journal of the American College of Cardiology (2021)
Association of Wildfire Air Pollution and Health Care Use for Atopic Dermatitis and Itch
Authors: Raj P. Fadadu, Barbara Grimes, Nicholas P. Jewell, Jason Vargo, Albert T. Young, Katrina Abuabara, John R. Balmes, Maria L. Wei
Journal: JAMA Dermatology (2021)

Air pollution is a worldwide public health issue that has been exacerbated by recent wildfires, but the relationship between wildfire-associated air pollution and inflammatory skin diseases is unknown.
Evaluation and management of obesity hypoventilation syndrome an official american thoracic society clinical practice guideline: executive summary
Authors: Babak Mokhlesi, Juan Fernando Masa, Jan L Brozek, Indira Gurubhagavatula, Patrick B Murphy, Amanda J Piper, Aiman Tulaimat, Majid Afshar, Jay S Balachandran, Geraldo Lorenzi Filho
Journal: American Journal of Respiratory and Critical Care Medicine (2019)
A comprehensive transcriptome signature of murine hematopoietic stem cell aging
Authors: Arthur Flohr Svendsen, Daozheng Yang, KyungMok Kim, Seka Lazare, Natalia Skinder, Erik Zwart, Anna Mura-Meszaros, Albertina Ausema, Björn von Eyss, Gerald de Haan, Leonid Bystrykh
Journal: Blood (2021)
Risk factors for the development of cystic fibrosis related liver disease [2] (multiple letters)
Authors: Martijn G. Slieker, Judith M. Deckers-Kocken, Cuno S P M Uiterwaal, Cornelis K. Van Der Ent, Roderick H J Houwen, Carla Colombo, Pier Maria Battezzati, Andrea Crosignani
Journal: Hepatology (2003)
Mapping atopic dermatitis and anti–IL-22 response signatures to type 2–low severe neutrophilic asthma
Authors: Yusef Eamon Badi, Ana B. Pavel, Stelios Pavlidis, John H. Riley, Stewart Bates, Nazanin Zounemat Kermani, Richard Knowles, Johan Kolmert, Craig E. Wheelock, Sally Worsley, Mohib Uddin, Kjell Alving, Per S. Bakke, Annelie Behndig, Massimo Caruso, Pascal Chanez, Louise J. Fleming, Stephen J. Fowler, Urs Frey, Peter Howarth, Ildikó Horváth, Norbert Krug, Anke H. Maitland-van der Zee, Paolo Montuschi, Graham Roberts, Marek Sanak, Dominick E. Shaw, Florian Singer, Peter J. Sterk, Ratko Djukanovic, Sven-Eric Dahlen, Yi-Ke Guo, Kian Fan Chung, Emma Guttman-Yassky, Ian M. Adcock
Journal: Journal of Allergy and Clinical Immunology (2021)
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination
Authors: Rishi R. Goel, Sokratis A. Apostolidis, Mark M. Painter, Divij Mathew, Ajinkya Pattekar, Oliva Kuthuru, Sigrid Gouma, Philip Hicks, Wenzhao Meng, Aaron M. Rosenfeld, Sarah Dysinger, Kendall A. Lundgreen, Leticia Kuri-Cervantes, Sharon Adamski, Amanda Hicks, Scott Korte, Derek A. Oldridge, Amy E. Baxter, Josephine R. Giles, Madison E. Weirick, Christopher M. McAllister, Jeanette Dougherty, Sherea Long, Kurt D’Andrea, Jacob T. Hamilton, Michael R. Betts, Eline T. Luning Prak, Paul Bates, Scott E. Hensley, Allison R. Greenplate, E. John Wherry
Journal: Science Immunology (2021)

Novel mRNA vaccines for SARS-CoV-2 have been authorized for emergency use. Despite their efficacy in clinical trials, data on mRNA vaccine-induced immune responses are mostly limited to serological analyses. Here, we interrogated antibody and antigen-specific memory B cells over time in 33 SARS-CoV-2 naïve and 11 SARS-CoV-2 recovered subjects. SARS-CoV-2 naïve individuals required both vaccine doses for optimal increases in antibodies, particularly for neutralizing titers against the B.1.351 variant. Memory B cells specific for full-length spike protein and the spike receptor binding domain (RBD) were also efficiently primed by mRNA vaccination and detectable in all SARS-CoV-2 naive subjects after the second vaccine dose, though the memory B cell response declined slightly with age. In SARS-CoV-2 recovered individuals, antibody and memory B cell responses were significantly boosted after the first vaccine dose; however, there was no increase in circulating antibodies, neutralizing titers, or antigen-specific memory B cells after the second dose. This robust boosting after the first vaccine dose strongly correlated with levels of pre-existing memory B cells in recovered individuals, identifying a key role for memory B cells in mounting recall responses to SARS-CoV-2 antigens. Together, our data demonstrated robust serological and cellular priming by mRNA vaccines and revealed distinct responses based on prior SARS-CoV-2 exposure, whereby COVID-19 recovered subjects may only require a single vaccine dose to achieve peak antibody and memory B cell responses. These findings also highlight the utility of defining cellular responses in addition to serologies and may inform SARS-CoV-2 vaccine distribution in a resource-limited setting.
Abstract 13697: The Optimal Strategy for In-stent Restenosis at the Right Coronary Artery Ostial Lesion After Stent Implantation
Authors: Suguru Otsuru, Kazushige Kadota, Tahei Ichinohe, Shunsuke Kubo, Yusuke Hyodo, Koshi Miyake, Daiji Hasegawa, Yoshikazu Shigemoto, Seiji Habara, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto, Kazuaki Mitsudo
Journal: Circulation (2013)

Background: Drug-eluting stent (DES) has markedly reduced the incidence of in-stent restenosis (ISR); however, the incidence of ISR is still high. Thus, we investigated the optimal percutaneous cor...
Persistent Opioid Use Associated With Dental Opioid Prescriptions Among Publicly and Privately Insured US Patients, 2014 to 2018
Authors: Kao-Ping Chua, Hsou-Mei Hu, Jennifer F. Waljee, Romesh P. Nalliah, Chad M. Brummett
Journal: JAMA Network Open (2021)

This cohort study uses data from 3 MarketScan databases to compare the association of persistent opioid use with dental opioid prescriptions among publicly and privately insured patients in the United States from 2014 through 2018.
Re: Agrawal et al.: Collaborative Ocular Tuberculosis Study consensus guidelines on the management of tubercular uveitis – Report 2: guidelines for initiating antitubercular therapy in anterior uveitis, intermediate uveitis, panuveitis, and retinal vasculitis (Ophthalmology. 2021;128:277–287)
Authors: Dhananjay Shukla
Journal: Ophthalmology (2021)
The role of the human gut microbiota in colonization and infection with multidrug-resistant bacteria
Authors: Irene Wuethrich, Benedikt W. Pelzer, Yascha Khodamoradi, Maria J. G. T. Vehreschild
Journal: Gut Microbes (2021)

About 100 years ago, the first antibiotic drug was introduced into health care. Since then, antibiotics have made an outstanding impact on human medicine. However, our society increasingly suffers from collateral damage exerted by these highly effective drugs. The rise of resistant pathogen strains, combined with a reduction of microbiota diversity upon antibiotic treatment, has become a significant obstacle in the fight against invasive infections worldwide.Alternative and complementary strategies to classical "Fleming antibiotics" comprise microbiota-based treatments such as fecal microbiota transfer and administration of probiotics, live-biotherapeutics, prebiotics, and postbiotics. Other promising interventions, whose efficacy may also be influenced by the human microbiota, are phages and vaccines. They will facilitate antimicrobial stewardship, to date the only globally applied antibiotic resistance mitigation strategy.In this review, we present the available evidence on these nontraditional interventions, highlight their interaction with the human microbiota, and discuss their clinical applicability.